A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

Everolimus plus CHOP is effective for newly diagnosed, chemotherapy-naïve peripheral T-cell lymphoma patients with acceptable toxicity.

from Cancer via ola Kala on Inoreader http://ift.tt/1PVP8Or
via IFTTT